The present report deals with a study 2 of the effects of 2,3-dimercaptopropanol (BAL) in humans. It was designed to explore the range of doses which may be safely administered to humans in relation to the schedules of doses which have been found effective in the treatment of Lewisite poisoning in animals.
SUBJECTS
The experiments were carried out in 9 subjects, 8 females and 1 male, 7 colored and 2 white. Their ages ranged from 18 to 49. They all had secondary or tertiary lues. One had diabetes and another hypertension, and a third, rheumatic heart disease. Three were under active antiluetic treatment; the remaining ones had not received treatment for at least several months. PLAN In each of 4 cases the experiments were carried out in the outpatient clinic, the patient leaving the clinic after symptoms had subsided. In each of 5 cases the patient was placed in the hospital, and was discharged on the day following the last dose. The experiment was so conducted as to eliminate anticipation or fear as a factor in the subjective symptoms.
American Reference Standard BAL was used in a 10 per cent solution in peanut oil containing 20 per cent benzyl. benzoate (Hinson, Westcott and Dunning). It was injected deeply into the gluteal muscles.
In the general plan the subject was weighed and placed in bed or on an examining couch, where he remained throughout the experiment. The blood pressure, the heart rate, and in some cases .4 ml. of the 10 per cent solution). In those cases in which more than 1 injection was given in a day, the total doses varied from 8.0 to 20.0 mgm. per kgm. The latter amounts were administered in a period of from 8 to 10 hours.
In the dosage range employed in these experiments (3.0 to 5.0 mgm.) distinct cumulation occurred when doses were given at intervals of 30 minutes. The 30-minute interval, however, greatly reduced the toxicity, since 8.0 mgm. per kgm. at one time produced severe symptoms, while the same amount given in a dose of 5.0 mgm. and 3.0 mgm. with an interval of 30 minutes, produced relatively mild symptoms in the same person.
Cumulation also occurred when the second dose was given at an interval of 2 hours. It There is some indication of the development of tolerance to BAL since, as may be seen in Table   II , the fourth, and sometimes the third, dose of 5.0 mgm. produced less severe symptoms than the first.
Symptoms. The pattern of symptoms varied from case to case (see Table II ). Vomiting was usually associated with the most severe reactions. In the course of the more severe reactions, the patients showed paresthesias (burning or tingling of the nose, eyes, mouth or skin), pain (involving the limbs, jaws, abdomen, chest and head), lacrimation, blepharospasm, and salivation. An indescribable sense of illness developed with extreme unrest and apprehension. Occasionally the patient perspired freely and complained of being very warm. As the symptoms subsided, most patients with the more severe reactions complained of weakness and fatigue. At 4 hours after the 5.0 mgm. doses they were free of systemic symptoms.
While most doses caused some pain during the injection, a moderately tender area in the region of the injection, still present some hours later, was encountered in 4 of the 9 cases.
The complete protocols of the experiments are appended.
Schedules. Single doses of BAL of from 5 to 8 mgm. per kgm. intramuscularly in man produced reactions which did not appear to be dangerous, so also for total doses of 20 mgm. per kgm. in fractions of 5 mgm. over a period of 8 hours.
A single dose of 5 mgm. per kgm. caused no symptoms in 50 per cent of the cases, negligible effects in 25 per cent, and slight and fleeting symptoms in the remaining 25 per cent. The course of the reaction is fairly brief, lasting approximately an hour. The indications are that a schedule of dosage involving 5 mgm. per kgm. for 4 doses at intervals of 3 hours is likely to show little cumulation. In such a schedule, the effects of the first dose are not likely to become greater as a result of its repetition. The effect of the third and fourth dose may actually be less. Shorter intervals with such doses, namely 2 hours or less, result in cumulation.
The review by Waters and Stock (1) indicates that others have obtained substantially similar results (2, 3).
SUMMARY AND CONCLUSIONS 1. The toxic effects of BAL by intramuscular injection were studied in 9 human subjects with secondary or tertiary lues.
2. The results are based on 28 injections of single doses of from 3 to 8 mgm. per kgm.
3. In man BAL produces paresthesias (burning or tingling of the nose, eyes, mouth, and skin), perspiration and sense of warmth, pain (limbs, jaws, abdomen, head), lacrimation, blepharospasm, salivation, vomiting, unrest, apprehension, weakness, and fatigue. The heart rate is accelerated and both systolic and diastolic blood pressure usually increased.
4. The minimal dose which produces toxic effects lies between 3 and 5 mgm. per kgm. A single dose of 8 mgm. produces marked symptoms.
5. 
